Karen Basbaum
Corporate Officer/Principal bei POSEIDA THERAPEUTICS, INC.
Profil
Karen Basbaum is currently the Senior Vice President-Business Development at Poseida Therapeutics, Inc. She previously held positions as the Director-Business Development at Amylin Pharmaceuticals, Inc., the Senior Vice President-Business Development at DNAtrix, Inc., the Vice President-Business Development at Elcelyx Therapeutics, Inc. from 2016 to 2017, and the Vice President-Business Development at Dauntless Pharmaceuticals, Inc. from 2017 to 2019.
Ms. Basbaum has a graduate degree from Rensselaer Polytechnic Institute, an undergraduate degree from the University of North Dakota, and an MBA from the Paul Merage School of Business.
Aktive Positionen von Karen Basbaum
| Unternehmen | Position | Beginn |
|---|---|---|
| POSEIDA THERAPEUTICS, INC. | Corporate Officer/Principal | 01.07.2020 |
Ehemalige bekannte Positionen von Karen Basbaum
| Unternehmen | Position | Ende |
|---|---|---|
Dauntless Pharmaceuticals, Inc.
 Dauntless Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Dauntless Pharmaceuticals, Inc. develops specialty therapeutics via a one-asset, one-company model that is structured to facilitate operational efficiencies. The company was founded by Joel F. Martin and Michael F. Powell in May 2015 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.02.2019 |
Elcelyx Therapeutics, Inc.
 Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.01.2017 |
DNAtrix, Inc.
 DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Corporate Officer/Principal | - |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Ausbildung von Karen Basbaum
| Rensselaer Polytechnic Institute | Graduate Degree |
| University of North Dakota | Undergraduate Degree |
| Paul Merage School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| POSEIDA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
DNAtrix, Inc.
DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Electronic Technology |
Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | Health Technology |
Dauntless Pharmaceuticals, Inc.
Dauntless Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Dauntless Pharmaceuticals, Inc. develops specialty therapeutics via a one-asset, one-company model that is structured to facilitate operational efficiencies. The company was founded by Joel F. Martin and Michael F. Powell in May 2015 and is headquartered in San Diego, CA. | Retail Trade |
